| |
Tuesday, August 27, 2024 | 12pm ET / 9am PT Join us for a one-hour, comprehensive discussion on the importance of leveraging federated AI for innovative data collection in real-world research. Register now.
|
|
Today’s Big NewsAug 14, 2024 |
| By Nick Paul Taylor Metagenomi is editing its pipeline, choosing to seek a partner for a program Moderna dropped and axing its amyotrophic lateral sclerosis activities in response to setbacks at a competitor. |
|
|
|
By James Waldron Evotec has set its sights on scrapping about 400 roles as the German company continues to battle tough market conditions. |
By Gabrielle Masson Galera Therapeutics is shuttering, with the biotech’s board OK'ing a liquidation plan that whittles down the company’s workforce to just three people. |
By Darren Incorvaia Despite maintaining its recent winning streak in the clinic, Acelyrin is no longer focused on its former lead asset izokibep. |
By James Waldron Kezar Life Sciences is dropping its unpromising phase 1 solid tumor drug as the biotech goes all-in on its lead autoimmune hepatitis program. |
By Nick Paul Taylor Viracta Therapeutics is going all-in on its lymphoma program. The biotech responded to phase 2 data by throwing its resources behind a plan to file for a blood cancer approval in 2026, hitting pause on its solid tumor program and putting 23% of its staff out of a job in the process. |
By Darren Incorvaia Neo is a free-floating, ephemeral gene that is made by bacteria only when they are infected by a virus—it doesn't exist anywhere in the genome. |
By Kevin Dunleavy Johnson & Johnson and Roche are at the top of S&P Global’s pharmaceutical industry power ratings, which assess the strength of the world’s top 17 drugmakers. |
By Conor Hale The Biden administration will deliver $150 million in cancer moonshot funds to new tech that aims to make tumor surgeries safer and more precise. |
By Darren Incorvaia Oncology-focused CRO Pi Health has added a new chef to its executive kitchen by appointing Alex Morozov, M.D., Ph.D., as its first chief medical officer. |
By Andrea Park With analysts estimating that millions of jobs in the STEM fields are currently going unfilled in the U.S., Moderna is doing its part to strengthen the workforce and close that gap. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," we’re diving into Fierce Biotech’s annual Fierce 15 special report. |
|
|---|
|
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
